Liver interleukin-8 messenger RNA expression and interferon sensitivity-determining region mutations relate to treatment response in hepatitis C 1b

Antiviral Therapy

Volumn 16, Issue 6, 2011, Pages 825-832

  Lee, Chuan Mo ^a,b   Yen, Yi Hao ^a,b   Hung, Chao Hung ^a,b   Lu, Sheng Nan ^a,b   Wang, Jing Houng ^a,b   Wang, Jyh Chwan ^a,b   Chen, Chien Hung ^a,b   Kee, Kwong Ming ^a,b   Hu, Tsung Hui ^a,b   Changchien, Chi Sin ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; COMPLEMENTARY DNA; INTERLEUKIN 8; MESSENGER RNA; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; FEMALE; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; INTERLEUKIN-8; LIVER; MALE; MIDDLE AGED; MUTATION; RNA, MESSENGER; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 80052920653     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1868     Document Type: Article

References (45)

1. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15:5-14.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35-S46. (Pubitemid 35253462)
3. Marcellin P, Boyer N, Gervais A, et al. Long-term histological improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127:875-881.
4. Yu ML, Lin SM, Chuang WL, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11:985-994.
5. Hung CH, Lee CM, Lu SN, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2006; 13:409-414.
6. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
7. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-2617. (Pubitemid 41007847)
8. Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12:283-291.
9. Lee CM, Kee KM, Hung CH, et al. Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection. Antivir Ther 2006; 11:17-23.
10. Yen YH, Hung CH, Hu TH, et al. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther 2008; 27:72-79.
11. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance. Nature 2009; 461:399-401.
12. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
13. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
14. Lee CM, Lu SN, Hung CH, et al. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical Implications. Trans R Soc Trop Med Hyg 2006; 100:767-774.
15. Podevin P, Sabile A, Gajardo R, et al. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner. Hepatology 2001; 33:1503-1511. (Pubitemid 32496988)
16. Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001; 75:6095-6106. (Pubitemid 32553140)
17. Gale M, Jr, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18:5208-5218. (Pubitemid 28388104)
18. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96:224-230.
19. Mukaida N, Harada A, Yasumoto K, et al. Properties of pro-inflammatory cell type-specific leukocyte chemotactic cytokines, interleukin 8 (IL-8) and monocyte chemotactic and activating factor (MCAF). Microbiol Immunol 1992; 36:773-789.
20. Murayama T, Kuno K, Jisaki F, et al. Enhancement human cytomegalovirus replication in a human lung fibroblast cell line by interleukin-8. J Virol 1994; 68:7582-7585. (Pubitemid 24328819)
21. Khabar KS, Al-Zoghaibi F, Al-Ahdal MN, et al. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha. J Exp Med 1997; 186:1077-1085. (Pubitemid 27441151)
22. Girard S, Shalhoub P, Lescure P, et al. An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology 2002; 295:272-283. (Pubitemid 34921313)
23. Wagoner J, Austin M, Green J, et al. Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J Virol 2007; 81:309-318. (Pubitemid 44975171)
24. Mihm U, Herrmann E, Sarrazin U, et al. Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. J Hepatol 2004; 40:845-852. (Pubitemid 38507367)
25. Fukuda R, Ishimura N, Ishihara S, et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996; 16:390-399. (Pubitemid 27042775)
26. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171. (Pubitemid 38428955)
27. Stuyver L, Wyseur A, van Arnhem W, et al. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34:2259-2266. (Pubitemid 26272214)
28. Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med 2006; 27:126-139.
29. Derveaux S, Vandesompele J, Hellemans J. How to do successful gene expression analysis using real-time PCR. Methods 2010; 50:227-230.
30. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520. (Pubitemid 24166476)
31. Yu ML, Chuang WL, Dai CY, et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res 2006; 148:120-127.
32. Pascu M, Martus P, Hohne M, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5AISDR: a meta-analysis focused on geographical differences. Gut 2004; 53:1345-1351. (Pubitemid 39120125)
33. Paterson M, Laxton CD, Thomas HC, et al. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 1999; 117:1187-1197. (Pubitemid 29512679)
34. Sarrazin C, Berg T, Lee JH, et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol 1999; 30:1004-1013. (Pubitemid 29278743)
35. Rehermann B, Chang K, McHutchinson JG, et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996; 70:7092-7102. (Pubitemid 26307425)
36. Bièche I, Asselah T, Laurendeau I, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005; 332:130-144. (Pubitemid 40127235)
37. Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005; 129:2064-2075. (Pubitemid 41772981)
38. Thornton AJ, Strieter RM, Lindley I, et al. Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in human hepatocytes. J Immunol 1990; 144:2609-2613. (Pubitemid 20136664)
39. Crotta S, Brazzoli M, Piccioli D, Valiante NM, Wack A. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J Hepatol 2010; 52:183-190.
40. Clément S, Pascarella S, Conzelmann S, Gonelle-Gispert C, Guilloux K, Negro F. The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8. J Hepatol 2010; 52:635-643.
41. Koo BC, McPoland P, Wagoner JP, Kane OJ, Lohmann V, Polyak SJ. Relationships between hepatitis C virus replication and CXCL-8 production in vitro. J Virol 2006; 80:7885-7893. (Pubitemid 44182289)
42. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86:23-32.
43. Sirén J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFNbeta, IL-28, and IL-29. J Immunol 2005; 174:1932-1937. (Pubitemid 40223933)
44. Hertzog PJ, O'Neill LA, Hamilton JA. The interferon in TLR signaling: more than just antiviral. Trends Immunol 2003; 24:534-539. (Pubitemid 37205204)
45. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311:1-16. (Pubitemid 47413193)